Dr. Stephen Monks is a seasoned developer of biological drugs with over twenty years of technical management experience at startup and mid-sized biotech companies where he helped navigate the development pathway for complex biologics within quality and regulatory frameworks. He currently serves as CEO and founder at GSL CMC Consulting in Lexington, MA. Previously, he held technical leadership positions at Pyxis Oncology, Aura Biosciences, and Agenus (formerly Antigenics) where he spent 14 years leading the manufacture, characterization and release of autologous therapeutics, recombinant biologics and the adjuvant QS-21. He had direct responsibility for oversight of Agenus’ CGMP manufacturing, clinical supply, CGMP warehousing and process and analytical development functions. Before that, Dr. Monks worked within the Genetics Institute’s R&D organization and preceding that, he completed a Howard Hughes postdoctoral fellowship at Brandeis University. Dr. Monks received his B.S., with honors, from the University of Queensland in Australia and his Ph.D. in Biochemistry from the University of Melbourne, also in Australia.